 |
|
|
| |
Bemnifosbuvir is a potent HCV NS5B inhibitor with a favorable antiviral profile and high resistance barrier
|
| |
| |
European Association for the Study of the Liver (EASL) 2024 Congress, 5-8 June, Milan, Italy.
Qi Huang, Dawei Cai, Steven Good, Nancy Agrawal, and Jean-Pierre Sommadossi
Atea Pharmaceuticals, Inc., Boston, MA, USA
|
| |
|
|
|
|
|
